What Must Be Prepared Before Renewing a Medical Device Registration in Japan?

What must be prepared before renewing a medical device registration in Japan?

Before renewing a medical device registration in Japan, a company should first confirm the target country, the product's risk class, the applicable regulatory pathway and the existing documentation base, and then assess its technical file, quality management system, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing documents or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, deficiency letters and rework are likely to arise in model coverage, evidence-chain consistency, labelling claims and certificate control. AIMEILI recommends planning this topic within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in each market rather than rebuilding documentation country by country.

Compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's own documentation base.

Content structure

• Key summary
• Applicable scenarios and core questions
• Registration decision logic
• Documents and evidence
• Common errors
• Manufacturer preparation checklist
• AIMEILI viewpoint
• Frequently asked follow-up questions
• Project execution recommendations
• Quality system and evidence consistency
• Localization conversion and agent responsibility
• Post-market maintenance and long-term planning
• Continue reading
• Content review and scope of application

Key summary

On the question of what must be prepared before renewing a medical device registration in Japan, a company should first confirm the target country, the product's risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing documents or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, deficiency letters and rework are likely to arise in model coverage, evidence-chain consistency, labelling claims and certificate control. AIMEILI recommends planning this topic within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in each market rather than rebuilding documentation country by country.

Applicable scenarios and core questions

Companies searching for what must be prepared before renewing a medical device registration in Japan are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why the timeline is being extended, and which issues will affect the launch plan. Behind this question there are often several linked topics at the same time: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states at the same time, or markets in Southeast Asia, the Middle East and Latin America, answering the procedure for a single country is not sufficient. A more valuable approach is to first turn the core technical file, quality system evidence, performance verification, clinical evidence and labelling and instructions for use into reusable versions, and then localize them according to each country's regulatory requirements.

Registration decision logic

A company should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether the device is sterile, whether it is active, and whether it contains software or has IVD attributes, before determining the risk class and the submission pathway. Once the pathway judgement is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains the renewal documentation. If these issues are left vague in the commercial contract, the company's market control can easily be affected at a later stage.

Documents and evidence

Documents commonly required include the product description, the model and specification matrix, intended use, the basis for risk classification, ISO 13485 or other applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the model coverage of test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. What regulators examine is whether the product is safe, effective and traceable for its intended purpose, not how many documents have been uploaded.

Common errors

The most common problem is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting domestic NMPA documentation after direct translation, without reordering the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling provide insufficient coverage.
• Selecting a local agent purely on the basis of a sales partnership, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration dossier claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country document reuse in advance, so that documentation is re-prepared for every country, multiplying both cost and timeline.

Manufacturer preparation checklist

Before starting a project, companies are advised to confirm their documentation base against an internal checklist, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, the model and specification matrix, and the intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI viewpoint

AIMEILI recommends that companies not treat target market registration as a one-off document submission, but manage it as an overseas market access programme. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than preparing documents on an ad hoc basis for each country, and it also supports subsequent changes and renewals more effectively.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway judgement; second, consistency of the document evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still go through repeated cycles in deficiency responses, agent communication and post-market maintenance, even when the documentation appears extensive.

Business impact: documentation gaps and unclear responsibility boundaries do not only delay a renewal in Japan. They affect launch timing, distributor commitments, tender participation or hospital listing schedules in the region, and they can also limit the company's ability to reuse the same evidence base for other GHWP member states. Early gap assessment and a defined certificate control structure are therefore commercial decisions as much as regulatory ones.

Frequently asked follow-up questions

Can domestic documentation be used directly for registration in a target market?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it stands. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

A gap assessment should be started immediately after the target market and product list are confirmed. The earlier it is completed, the easier it is to schedule additional testing, translation, label adaptation and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in regulatory communication, changes, renewal and the handling of post-market events. If rights and responsibilities are unclear, certificate control and the stability of the subsequent market position can be affected.

Which documents influence renewal most?

In practice, the documents that most often determine the pace of a renewal project are the technical file and its consistency, the quality system evidence covering the manufacturing site, labelling and instructions for use, authorization documents, clinical evidence, and post-market surveillance records. These should be reviewed as a single evidence set rather than as separate administrative items.

Project execution recommendations

When executing this type of registration project, companies should maintain a project register that consolidates the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented with explanations for a particular country. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway judgement.
• Establish the documentation gap assessment table.
• Define the local agent and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibility in advance.

Quality system and evidence consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators generally examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model specifications or IFU version differ from the test reports, the authority may request supplementary explanations even when a large volume of documentation has been prepared.

Before submission, companies should establish an evidence consistency check table that maps the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificate item by item. This appears basic, but it can clearly reduce the probability of deficiency letters, especially for projects submitted simultaneously in several GHWP member states or across multiple product families.

Localization conversion and agent responsibility

Target market registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly influence certificate control and the stability of the subsequent market position.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-market maintenance and long-term planning

Completion of registration does not mean that compliance work has ended. Companies must also maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so that when a manufacturing address change, model extension, IFU update or agent replacement occurs, the certificate and commercial sales activities become disconnected.

AIMEILI recommends managing this topic within the annual international registration plan: first define target market priorities, then build a reusable document package and a national gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach lies not only in improving registration efficiency in a single country, but also in helping companies build a repeatable overseas compliance capability and reduce the cost of repackaging documentation from scratch every time they enter a new market.

Continue reading

• Previous: When must a change be filed for a medical device registration in Japan?
• Next: How are multiple models grouped for submission in a medical device registration in Japan?
• Recommended reading: How should a local agent be selected for medical device registration in Brazil?
• Recommended reading: How are authorized representative responsibilities divided in medical device registration in Brazil?
• Recommended reading: Why do medical device registration timelines in Brazil become extended?
• Recommended reading: What are the common reasons for deficiency letters in Brazilian medical device registration?
• Recommended reading: How is post-market surveillance conducted for medical device registration in Brazil?
• Recommended reading: When must a change be filed for medical device registration in Brazil?

Content review and scope of application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only to support judgement. Scope of application: this article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.

Published: 15 July 2026, 19:38; Updated: 15 July 2026, 19:38